L3VLUP
ProSign in

ADMA · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ADMAGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ADMA
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterADMAGILD
Q3 20202 holders, $6.2m25 holders, $14.2bn
Q4 2020none listed holders, n.a.27 holders, $13.4bn
Q1 2021none listed holders, n.a.24 holders, $14.5bn
Q2 2021none listed holders, n.a.18 holders, $14.9bn
Q3 2021none listed holders, n.a.20 holders, $16.4bn
Q4 2021none listed holders, n.a.20 holders, $16.8bn
Q1 20221 holders, $4.2m28 holders, $13.2bn
Q2 20221 holders, $4.3m26 holders, $13.6bn
Q3 20221 holders, $4.9m24 holders, $13.3bn
Q4 20222 holders, $7.4m32 holders, $21.1bn
Q1 20231 holders, $678k27 holders, $21.8bn
Q2 20232 holders, $11m24 holders, $20.7bn
Q3 20231 holders, $11m24 holders, $20.0bn
Q4 20232 holders, $13m22 holders, $21.5bn
Q1 20244 holders, $62m30 holders, $20.3bn
Q2 20246 holders, $225m28 holders, $18.5bn
Q3 20248 holders, $378m29 holders, $24.2bn
Q4 20247 holders, $209m28 holders, $25.9bn
Q1 20257 holders, $187m33 holders, $32.0bn
Q2 20256 holders, $88m27 holders, $30.9bn
Q3 20254 holders, $221m23 holders, $29.4bn
Q4 20258 holders, $464m25 holders, $34.3bn
Q1 20263 holders, $106m25 holders, $38.5bn
Q2 20261 holders, $73m26 holders, $34.2bn
ADMA

Adma Biologics Inc

Holders
7
Reported value
$209m
Buyers
3
Sellers
3

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
28
Reported value
$25.9bn
Buyers
14
Sellers
14

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ADMA (2)

Arrowstreet Capital LP, Freestone Grove Partners LP

Only GILD (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, PDT Partners LLC, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Verition Fund Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →